← All trials
NCT06380699
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 16, 2023
- Primary completion
- Nov 16, 2023
- Completion date
- Dec 25, 2023
- First posted
- Apr 24, 2024
- Last posted
- Jul 24, 2024
- Enrollment
- 56
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ChinaLead sponsor
- Nanjing UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.